Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9 Breast 6 Gynecologic 4 Sarcoma 3 Other solid neoplasm 3 Gastrointestinal 3 Other hematologic neoplasm 2 Genitourinary 2 Tumor-Agnostic 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 157 Nivolumab 132 Ipilimumab 77 Cyclophosphamide 46 Specimen Handling 44 Magnetic Resonance Spectroscopy 39 cemiplimab 35 Biopsy 31 fludarabine 28 trametinib 24 relatlimab 24 binimetinib 23 Interleukin-2 21 fludarabine phosphate 20 dabrafenib 20 atezolizumab 20 Radiotherapy 20 Opdualag 19 Radiosurgery 18 CTLA-4 Antigen 18 encorafenib 17 aldesleukin 17 Blood Specimen Collection 17 avelumab 14 Immunoglobulin G 14 Disulfides 13 lenvatinib 11 Bevacizumab 11 lifileucel 10 Paclitaxel 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

ceralasertib × Dermatologic × 1 year × Clear all

NCT05061134 2025-07-31

MONETTE

AstraZeneca

Phase 2 Active not recruiting

194 enrolled 21 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡